Dupixent Lawsuit Lawyers: T-Cell Lymphoma (CTCL) Claims

Last Updated: November 13, 2026

The Dupixent lawsuit is a group of product liability cases claiming that Dupixent (dupilumab), an injectable drug for eczema, asthma and related conditions, can cause, speed up or hide cutaneous T-cell lymphoma, and that Sanofi and Regeneron did not warn patients or doctors. Many of the people filing were treated for what looked like stubborn eczema and learned months or years later that it was a rare cancer of the skin.

Fob & Foster Personal Injury Lawyers review Dupixent lymphoma claims for people in Alabama, Georgia and Tennessee. This page covers who qualifies, where the federal litigation stands, what the science does and does not show, whether there is a class action or a settlement, and how each state’s deadline works.

Who Qualifies for a Dupixent Lawsuit?

We look for three things, and all three come from records.

The strongest claims share a pattern: a rash treated as eczema, a period on Dupixent in which the skin improved and then worsened or changed, and a biopsy that finally showed lymphoma. A diagnosis of another T-cell lymphoma after Dupixent is also worth a review. These cases are about T-cell lymphoma. Other diagnoses generally fall outside them, and we will tell you if that is your situation.

Dupixent Lawsuit Updates

We keep this dated history in one place. Our state pages for Alabama, Georgia and Tennessee carry the latest update and link back here, and our Dupixent lawsuit update post summarizes each month.

What Is the Dupixent Lawsuit?

Dupixent is an injectable biologic made by Sanofi and Regeneron. The FDA approved it in 2017, and its approved uses have grown to include moderate-to-severe eczema (atopic dermatitis), certain types of asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, prurigo nodularis and COPD. It works by blocking part of the immune system’s inflammatory signaling, and for many patients it has worked where nothing else did.

The lawsuits rest on one core allegation: that Sanofi and Regeneron knew or should have known that Dupixent could cause, accelerate or unmask cutaneous T-cell lymphoma in some patients, and failed to warn doctors or patients. These are allegations. The companies deny them, and no court has ruled on the merits.

What Is Cutaneous T-Cell Lymphoma?

Cutaneous T-cell lymphoma, or CTCL, is a rare blood cancer that shows up in the skin. Its most common form is mycosis fungoides. Sézary syndrome is a more aggressive form that also involves the blood. Early CTCL looks a great deal like eczema: red, scaly, stubbornly itchy patches. That resemblance sits at the center of both the science and the lawsuits, because a drug prescribed for presumed eczema can end up being given to someone whose rash was early lymphoma that had not yet been diagnosed.

Stage matters. Early-stage CTCL and advanced CTCL are very different diseases to have, which is why a delay in diagnosis is itself part of the harm these cases describe.

Does Dupixent Cause Cancer? What the Evidence Shows

No regulator has concluded that Dupixent causes cancer. Here is what is on the record:

These findings describe association, not proof of causation. A safety signal is not a conclusion; it means the reporting data looks unusual enough that the agency is investigating. People with severe, treatment-resistant “eczema” may also include an unusual number of undiagnosed early CTCL cases, which by itself would raise the numbers. How much of the signal is the drug and how much is the diagnosis is what the FDA review and the experts in the litigation will fight over. Our article Does Dupixent Cause Cancer? goes through the evidence and its limits in more detail.

The Masking Problem

The most serious allegation is not only that Dupixent might cause lymphoma. It is that Dupixent can hide it. Plaintiffs allege that by suppressing visible inflammation, the drug can make early CTCL look as if it is improving, which reinforces the eczema diagnosis while the cancer advances. In several reported cases, patients improved at first, then worsened in ways eczema should not, and only a later biopsy revealed lymphoma at a more advanced stage.

The practical advice is concrete. If you are on Dupixent and your skin stops behaving like eczema, comes back in new patterns or never fully responds, ask your dermatologist directly whether a biopsy is warranted.

Has Dupixent Been Recalled? What the Label Says

Dupixent has not been recalled. As of November 2026 its FDA-approved prescribing information does not mention CTCL, mycosis fungoides, Sézary syndrome or lymphoma. A label update in February 2026 added a new rhinosinusitis indication and no cancer warning. That silence is what the failure-to-warn claims are about.

Is There a Dupixent Class Action Lawsuit?

No. The Dupixent cases are individual lawsuits grouped in a multidistrict litigation, MDL 3180, for pretrial work. Nobody is included automatically and there is no claim form. Any recovery would be based on your own diagnosis and your own records, and you have to file your own case before your own deadline.

Where the Dupixent MDL Stands

Individual Dupixent lymphoma suits were filed around the country through 2025. On February 13, 2026, plaintiffs asked the Judicial Panel on Multidistrict Litigation to centralize them and proposed the Northern District of Georgia, which then held more Dupixent cases than any other district. Sanofi and Regeneron agreed an MDL was appropriate but argued for New York. On June 4, 2026, the Panel created MDL 3180 in the District of New Jersey before Judge Zahid N. Quraishi and transferred 15 cases plus 7 tag-along actions.

A docket of 40 cases is small. That is normal for an MDL five months old, and new cases can be filed directly into it. A small docket also means the early cases get close attention: the facts in the first profile forms help shape how both sides, and the judge, come to see the litigation.

What the First Phase of the MDL Will Decide

Plaintiff-side reports describe a schedule in two phases. The first asks a single question that applies to every case: can Dupixent cause, speed up or unmask T-cell lymphoma at all? Lawyers call this general causation. Each side will put forward experts in dermatology, oncology and epidemiology, and the judge will decide which opinions are reliable enough for a jury to hear.

That ruling matters to every person with a claim. If the court excludes the plaintiffs’ experts, most cases end there. If it allows them, the litigation moves to the second phase, where individual cases are worked up and the first trial cases are chosen. While that fight goes on, each plaintiff fills out a profile form about the prescription, the diagnosis and the treatment. Those forms are reported to begin on December 18, 2026.

Who Is Being Sued, and What They Say

The defendants are Sanofi and Regeneron Pharmaceuticals, which developed Dupixent together and sell it. Neither company has recalled the drug or changed the label to mention lymphoma. Both deny that Dupixent causes T-cell lymphoma, and they will argue that patients with severe, long-running skin disease were already at higher risk of having an undiagnosed lymphoma before the first injection. Expect that argument in every case. It is the reason the timeline of your own rash, biopsies and treatment matters so much.

Has the Dupixent Lawsuit Been Settled?

No. No settlement has been announced, no trial has been held, and there is no payout to report. Before anyone talks about money, the court has to decide whether the science supports the claim that Dupixent can cause T-cell lymphoma. That question comes first in the schedule. Our Dupixent lawsuit update explains what has to happen before settlements become realistic.

What a Dupixent Claim Can Recover

A recovery in a drug injury case is built from the harm itself: the cost of cancer treatment already received and still to come, lost income, pain, and the effect of the disease on daily life. In a case built on delayed diagnosis, the difference between the stage at which the lymphoma was found and the stage at which it could have been found is central. Families who lost someone may have a wrongful death claim under their state’s law.

Whatever a case recovers, the number a person takes home is smaller than the gross figure. The attorney fee and case costs come out, and so does any repayment owed to Medicare, Medicaid or a private health plan that paid for the cancer treatment. We put those numbers in writing before a client decides anything, and you should expect the same from any firm you speak with.

How a Dupixent Claim Works, Step by Step

• A free review. We go over when you started Dupixent, what your skin did on the drug, and when the lymphoma was diagnosed.
• Records. With your permission we request the pharmacy history, the dermatology chart and every pathology report. You pay nothing up front.
• Filing. If the claim fits, a complaint is filed in your name. New cases can be filed directly into MDL 3180 in New Jersey, and most people never travel there.
• The profile form. Each plaintiff answers the court’s questions about the prescription, the diagnosis and the treatment, with records attached.
• Waiting on the science ruling. Individual cases will not move far until the court decides the general causation question.

How Long Do You Have to File?

• Alabama: generally two years (Ala. Code § 6-2-38). See our Alabama Dupixent page.
• Georgia: generally two years (O.C.G.A. § 9-3-33), with a ten-year statute of repose on product liability claims (O.C.G.A. § 51-1-11(b)). See our Georgia Dupixent page.
• Tennessee: generally one year (Tenn. Code Ann. § 28-3-104), with outer limits under the state’s product liability act (§ 29-28-103). See our Tennessee Dupixent page.

With CTCL the starting date is often disputed, because the cancer is so often treated as eczema for months or years before anyone takes a biopsy. Many patients first heard of a possible link after the FDA’s 2025 review became public. Do not assume either date helps you. Have someone look at your records.

Records That Prove a Dupixent Claim

• Pharmacy or specialty pharmacy records showing each Dupixent fill and the dates.
• Dermatology records from before and during treatment, including photographs if your doctor took them.
• Biopsy and pathology reports, including any earlier biopsies read as eczema or dermatitis.
• Oncology records with the staging and the treatment plan.
• A short timeline of when the rash began, when Dupixent started, when the skin changed and when the diagnosis came.

If Your Eczema May Have Been Lymphoma: Questions for Your Doctor

This is not medical advice, and your dermatologist or oncologist is the person to answer these. They are the questions our clients tell us they wish they had asked sooner:

• Has my skin ever been biopsied, and what did each report say?
• If an earlier biopsy was read as eczema or dermatitis, should it be looked at again?
• Does the way my rash changed on Dupixent call for a new biopsy?
• If I have been diagnosed, what stage is it, and when do you think it began?

Ask for a copy of every pathology report. Those reports, read in order, are often the clearest record of when the disease could have been caught.

What to Do This Week

• Do not stop a prescribed medicine on your own. Talk with your prescriber.
• If your rash is not behaving like eczema, ask about a biopsy.
• Request your pharmacy fill history and your pathology reports.
• Write down the date you first learned Dupixent might be connected to your diagnosis.

How We Handle Dupixent Claims

• You speak with a lawyer. Fob James IV is licensed in Alabama, Georgia and Tennessee.
• No fee unless we recover for you. The review costs nothing, and we request the records.
• A direct answer. If your diagnosis or your dates do not fit the current cases, we say so in the review.

Dupixent Lawyers for Alabama, Georgia and Tennessee

We are a Birmingham firm with a second office in Mobile, and we review Dupixent claims from across Alabama, Georgia and Tennessee by phone or video. You do not need a Dupixent lawyer near you, because the federal cases are handled together in New Jersey no matter where you live. What does differ by state is the deadline. Georgia held more Dupixent cases than any other federal district when the MDL was formed, and its two-year limit comes with a ten-year outer bar. Tennessee’s one-year limit is among the shortest in the country. If you are searching for a Dupixent attorney or law firm in Birmingham, Atlanta, Nashville or Memphis, the first thing we will ask for is your dates.

Talk to a Dupixent Lawsuit Lawyer

If you were diagnosed with a T-cell lymphoma after taking Dupixent, call Fob & Foster Personal Injury Lawyers at 866-837-1010 or request a free case review online. We ask when you started the drug, when the diagnosis came and when you first connected the two. Then we tell you whether the claim fits the current cases and how much time your state likely leaves you. There is no fee unless we recover for you.

Related Practice Areas

• Dupixent Lawsuit in Alabama
• Dupixent Lawsuit in Georgia
• Dupixent Lawsuit in Tennessee
• Dupixent Lawsuit: Monthly Update
• Does Dupixent Cause Cancer?
• Defective Product Claims